Platforms and initiatives

Large-scale investments in technology infrastructure for dementia research

Banner Blue Hexagons Technology Shutterstock Pluie R

To meet the challenge of developing treatments and technology for those living with dementia, we must be ambitious in our thinking and equip ourselves with the best tools, technology and resources. At the UK DRI, we’re committed to building initiatives and infrastructure that provide a catalyst to groundbreaking dementia research taking place across the UK.

In just our first few years, we have launched three multi-million-pound Director’s Strategic Initiatives that will help drive scientific breakthroughs in the dementia field.

Map Graphic

Launched in March 2020, the Multi-‘omics Atlas Project (MAP) is a £2M Directors’ initiative led by UK DRI at Imperial, which aims to create an ‘atlas’ of the brain at different stages of Alzheimer’s disease. It is the first time that UK brain tissue resources have been coordinated on such a scale to study Alzheimer’s disease pathology at every stage of the condition, and is set to rapidly improve our understanding of the processes that lead to people developing the condition.

The project is managed by Senior Scientific Project Manager, Dr Johanna Jackson, under the leadership of Centre Director, Prof Paul Matthews. The team use an unprecedented range of advanced techniques to examine tissue from eight different regions of the brain. The aim is to gain a much fuller understanding of key cell characteristics, including what influences the genes of individual cells to be expressed, and the role of proteins and other factors on their function. The data obtained is combined with information gathered from microscopic examination of the tissue, and with the medical history of each brain donor. Powerful new molecular imaging technology are used to examine subtle but important differences in cell types and their relationships in the brain. From these data, scientists are able to develop a better understanding of how individual cells function and interact with their environment.

Find out more about the MAP from the launch news article and dedicated MAP website.

Stem Cells 3 D Red Kateryna Kon

Launched in April 2021, the IPSC Platform to Model Alzheimer’s Disease Risk (IPMAR) is a major initiative led by UK DRI at Cardiff, which aims to become one of the largest cellular model resources available to study Alzheimer’s, helping researchers worldwide explore risk factors that contribute to development of the disease.

Alzheimer’s disease is a multifactorial and extremely complex condition. In the majority of cases, the risk of developing it is determined by thousands of small contributions from our genes, along with environmental factors such as lack of exercise. Researchers have been analysing huge genetic datasets to generate polygenic risk scores (PRS), which are a calculation of an individual’s overall risk for developing Alzheimer’s. Led by Prof Julie Williams, Centre Director from UK DRI at Cardiff, the IPMAR team plan to create and validate up to 60 induced pluripotent stem cell (iPSC) lines from people with high or low polygenic risk for Alzheimer’s. These iPSCs can be transformed into nearly any cell type in the body, such as neurons or microglia immune cells, and will be an invaluable resource for modelling and studying the complex biology that the disease presents.

Find out more about the IPMAR from the launch news article.

Aav Hippocampus Smaller

Launched by UK DRI at King’s in 2019, the adeno-associated virus (AAV) platform aims to assist with the design and pre-clinical validation and clinical trials of AAV vectors capable of delivering long lasting, cost effective and safe therapies for neurodegenerative diseases.

In recent years there has been a resurgence in gene therapy efforts that is partly fuelled by the identification and understanding of new gene delivery vectors. AAV is a non-enveloped virus that can be engineered to deliver DNA to target cells, and has attracted a significant amount of attention in the field. Prof Chris Shaw, Centre Director from UK DRI at Kings, leads the team in the generation of gene therapy vectors at the UK DRI.

The team are specialists in the production of high-quality AAV, which they apply the Centre’s research into frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). They also advise UK DRI researchers across the Institute on the development, safety and efficacy testing and production of novel AAV tools.

Find out more about the adeno-associated virus platform in the launch news article.

Founding funders

Latest tweets from @UKDRI

RT @Daniell19244313: 👉Do you want to help people with neurodegenerative diseases live well in their own homes? 👉 Do you want to work within…
19 Jan 2022 19:21

RT @TheCrick: 📰 Researchers from @PataniLab have uncovered the diverse origins of #MND, which can converge to turn once helpful and protect…
19 Jan 2022 17:32